287 related articles for article (PubMed ID: 18336887)
21. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
23. Distinct expression of Survivin splice variants in breast carcinomas.
Vegran F; Boidot R; Oudin C; Riedinger JM; Lizard-Nacol S
Int J Oncol; 2005 Oct; 27(4):1151-7. PubMed ID: 16142334
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
25. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Yoo J; Lee YJ
Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
[TBL] [Abstract][Full Text] [Related]
26. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.
Suga K; Yamamoto T; Yamada Y; Miyatake S; Nakagawa T; Tanigawa N
Oncol Rep; 2005 May; 13(5):891-7. PubMed ID: 15809755
[TBL] [Abstract][Full Text] [Related]
27. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
Pennati M; Binda M; Colella G; Zoppe' M; Folini M; Vignati S; Valentini A; Citti L; De Cesare M; Pratesi G; Giacca M; Daidone MG; Zaffaroni N
Oncogene; 2004 Jan; 23(2):386-94. PubMed ID: 14724567
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance and different properties of survivin splicing variants in gastric cancer.
Meng H; Lu C; Mabuchi H; Tanigawa N
Cancer Lett; 2004 Dec; 216(2):147-55. PubMed ID: 15533590
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake.
Sato A; Ito K; Asano T; Sumitomo M; Asano T; Hayakawa M
Int J Oncol; 2007 Mar; 30(3):695-700. PubMed ID: 17273771
[TBL] [Abstract][Full Text] [Related]
30. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
Vaday GG; Peehl DM; Kadam PA; Lawrence DM
Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
[TBL] [Abstract][Full Text] [Related]
31. Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer.
Hou JQ; He J; Wang XL; Wen DG; Chen ZX
Chin Med J (Engl); 2006 Oct; 119(20):1734-9. PubMed ID: 17097022
[TBL] [Abstract][Full Text] [Related]
32. Survivin expression is associated with features of biologically aggressive prostate carcinoma.
Shariat SF; Lotan Y; Saboorian H; Khoddami SM; Roehrborn CG; Slawin KM; Ashfaq R
Cancer; 2004 Feb; 100(4):751-7. PubMed ID: 14770431
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
34. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer.
Atlasi Y; Mowla SJ; Ziaee SA
Cancer Detect Prev; 2009; 32(4):308-13. PubMed ID: 19186007
[TBL] [Abstract][Full Text] [Related]
36. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
37. CaT1 expression correlates with tumor grade in prostate cancer.
Peng JB; Zhuang L; Berger UV; Adam RM; Williams BJ; Brown EM; Hediger MA; Freeman MR
Biochem Biophys Res Commun; 2001 Apr; 282(3):729-34. PubMed ID: 11401523
[TBL] [Abstract][Full Text] [Related]
38. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer.
Dai H; Li R; Wheeler T; Diaz de Vivar A; Frolov A; Tahir S; Agoulnik I; Thompson T; Rowley D; Ayala G
Prostate; 2005 Nov; 65(3):276-86. PubMed ID: 16015593
[TBL] [Abstract][Full Text] [Related]
39. [Effect of downregulation of prostate cancer antigen-1 expression on malignant biological behavior of prostate cancer LNCaP cells].
Liu BQ; Wang YK; Wu YD; Wei JX; Li X
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):828-32. PubMed ID: 24447480
[TBL] [Abstract][Full Text] [Related]
40. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
Huang CL; Liu D; Nakano J; Yokomise H; Ueno M; Kadota K; Wada H
Clin Cancer Res; 2007 Dec; 13(23):6938-46. PubMed ID: 18056168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
